Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Other Accumulated Expenses (2020 - 2025)

Abvc Biopharma (ABVC) has disclosed Other Accumulated Expenses for 6 consecutive years, with $470133.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 9.31% year-over-year to $470133.0, compared with a TTM value of $470133.0 through Dec 2025, up 9.31%, and an annual FY2025 reading of $470133.0, up 9.31% over the prior year.
  • Other Accumulated Expenses was $470133.0 for Q4 2025 at Abvc Biopharma, down from $575578.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $728576.0 in Q2 2025 and bottomed at $961.0 in Q4 2022.
  • Average Other Accumulated Expenses over 4 years is $359503.1, with a median of $424688.5 recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 17915.82% in 2023, then dropped 12.69% in 2024.
  • Year by year, Other Accumulated Expenses stood at $961.0 in 2022, then surged by 17915.82% to $173132.0 in 2023, then soared by 148.43% to $430107.0 in 2024, then increased by 9.31% to $470133.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for ABVC at $470133.0 in Q4 2025, $575578.0 in Q3 2025, and $728576.0 in Q2 2025.